Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2023 | Prioritizing diversity in Alzheimer’s disease biomarker studies

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, gives insight into the need for more diverse cohorts to improve our understanding of the impact of sex, age, and race on biomarker levels and trajectories in Alzheimer’s disease. While efforts to study racial and ethnic minority populations have improved, much of the evidence collected to date comes from homogeneous research cohorts. The recruitment of diverse participants allows for the improved generalizability of study results, as well as a greater understanding of disease disparity. For example, in the United States, Hispanics are 1.5 times more likely to develop Alzheimer’s than white Americans, but the mechanisms underlying this remain unknown. Discerning how these factors influence biomarker cut-offs, ranges, and trajectories is key for moving forwards towards clinical use. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Suzanne Schindler reports the following disclosures: scientific advisory board for Eisai.